The global demand for Nuclear Medicine Isotopes Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028. Whereas with regards to volume, the market was calculated XX Kilo Tons in 2019 and foreseen to touch XX Kilo Tons by 2026 with a CAGR of XX% during 2020-2026.
Nuclear medicine isotope is a medical science that uses radioactive sources, atoms, and molecules to diagnose, characterize, and treat disease. Physicians rely on isotopes for different applications depending on their chemical and radioactive decay properties. Technetium-99m, thallium-201, iodine, fluorine-18, rubidium-82, and iodine-131 are widely used nuclear medicine. Among these, technetium-99m is most employed of all nuclear medicine procedures. Nuclear medicine includes brachytherapy, radioembolic therapy, and targeted internal radionuclide therapy (TIRT).
Rising preference for non-invasive treatment and growing benefits of isotopes medicine is stimulating the growth of the global nuclear medicine isotopes market. Nuclear isotopes medicines are less common than other counterparts. The non-invasive nature, together with the ability to observe an organ functioning outside the body, makes this technique a powerful diagnostic tool. In medical diagnosis, there is a strong trend to use nuclear isotopes. Several medical research is being conducted globally to use radionuclides for highly specific biological chemicals such as immunoglobulin molecules. A favorable response from the study is estimated to propel the market growth. However, low acceptance and awareness about nuclear medicine isotopes among people hampers the growth of the market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of nuclear medicine isotopes.
The entire nuclear medicine isotopes market has been sub-categorized into type and application. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Technetium-99m (Tc-99m)
- Thallium-201 (Tl-201)
- Iodine (I-123)
- Rubidium-82 (Rb-82)
- Iodine-131 (I-131)
- Lutetium-177 (Lu-177)
- Radium-223 (Ra-223) and Alpharadin
- Actinium-225 (Ac-225)
This section covers regional segmentation which accentuates on current and future demand for nuclear medicine isotopes market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Nuclear Medicine Isotopes Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the nuclear medicine isotopes market include GE Healthcare, NTP Radioisotopes SOC Ltd., Nordion (Canada) Inc., Cardinal Health, Inc., Bayer AG. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.